# **Special Issue**

# Targeted Radionuclide Tumor Therapy

# Message from the Guest Editors

In the era of personalized cancer treatment there has been a great emphasis on targeted therapy. Targeted radionuclide therapy represents a promising therapeutic strategy for the treatment of patients with disseminated cancer. The success of targeted radionuclide therapy in malignant lymphomas has proven that this approach is feasible, effective and clinically translatable. However, the full translation of this approach to solid tumours was restricted by low tumour accumulation, normal tissue toxicity and an intrinsically greater radioresistance. There has recently been progress in the treatment of solid tumours with targeted radionuclide therapy, particularly in patients with somatostatin receptorpositive neuroendocrine tumours. This has opened the door to the development of new radionuclide-based targeting agents with therapeutic potential. As stated, the development of new targeted radionuclide therapies and their translation into clinical practice represents a great challenge in the field. This Special Issue has the aim of highlighting current progress in the development of potential targeting agents for targeted radionuclide therapy.

#### **Guest Editors**

Prof. Dr. Vladimir Tolmachev

Department of Immunology, Genetics and Pathology (IGP), Uppsala University, 751 85 Uppsala, Sweden

Dr. Mohamed Altai

Division of Oncology and Pathology, Department of Clinical Sciences, Kamprad Laboratory, Lund University, 22243 Lund, Sweden

# Deadline for manuscript submissions

closed (30 September 2019)



# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/21553

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

## **Author Benefits**

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

# **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

